Literature DB >> 32423426

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Hanren Dai1,2,3, Zhiqiang Wu1, Hejin Jia2, Chuan Tong1, Yelei Guo1, Dongdong Ti1, Xiao Han1, Yang Liu4, Wenying Zhang2, Chunmeng Wang2, Yajing Zhang2, Meixia Chen2, Qingming Yang2, Yao Wang5, Weidong Han6,7.   

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Entities:  

Year:  2020        PMID： 32423426      PMCID： PMC7236305          DOI： 10.1186/s13045-020-00878-2

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


  1 in total

1.  Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Authors:  Hanren Dai; Zhiqiang Wu; Hejin Jia; Chuan Tong; Yelei Guo; Dongdong Ti; Xiao Han; Yang Liu; Wenying Zhang; Chunmeng Wang; Yajing Zhang; Meixia Chen; Qingming Yang; Yao Wang; Weidong Han
Journal:  J Hematol Oncol       Date:  2020-04-03       Impact factor: 17.388
  1 in total
  1 in total

1.  Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.

Authors:  Punita Grover; Olivier Veilleux; Lu Tian; Ryan Sun; Melissa Previtera; Emily Curran; Lori Muffly
Journal:  Blood Adv       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.